Heron Therapeutics (HRTX)
(Real Time Quote from BATS)
$2.02 USD
0.00 (0.00%)
Updated Sep 20, 2024 03:00 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Heron Therapeutics (HRTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.75 | $9.00 | $5.00 | 234.16% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Heron Therapeutics comes to $6.75. The forecasts range from a low of $5.00 to a high of $9.00. The average price target represents an increase of 234.16% from the last closing price of $2.02.
Analyst Price Targets (4 )
Broker Rating
Heron Therapeutics currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 25% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
6/4/2024 | Northland Capital Markets | Carl Byrnes | Strong Buy | Strong Buy |
4/23/2024 | Capital One Securities | Timothy Chiang | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 4 |
Average Target Price | $6.75 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 82 of 253 |
Current Quarter EPS Est: | -0.03 |
HRTX FAQs
Heron Therapeutics, Inc. (HRTX) currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Heron Therapeutics, Inc. (HRTX) is $6.75. The current on short-term price targets is based on 2 reports.
The forecasts for Heron Therapeutics, Inc. (HRTX) range from a low of $5 to a high of $9. The average price target represents a increase of $234.16 from the last closing price of $2.02.
The current UPSIDE for Heron Therapeutics, Inc. (HRTX) is 234.16%
Based on short-term price targets offered by four analysts, the average price target for Heron Therapeutics comes to $6.75. The forecasts range from a low of $5.00 to a high of $9.00. The average price target represents an increase of 234.16% from the last closing price of $2.02.